Jonathan is a key member of ZS’s R&D excellence practice. Prior to joining ZS, he had more than 20 years of experience across large and small pharma companies.
Jonathan’s areas of expertise include clinical development, GCP quality, GCP risk management, quality management systems, process and vendor oversight, metrics and governance.
From 2014 through 2019, Jonathan was the global head of clinical development, quality performance and risk management at Pfizer, where his responsibilities included developing, monitoring, modeling and predicting the Pfizer GCP quality management system, leading the analysis of Pfizer’s clinical trial quality performance, and ensuring clinical trial quality risk management was built into all trials.
Earlier in his career, Jonathan held leadership roles in both large and startup pharma across clinical development, medical affairs, intellectual property strategy, portfolio management, business development and pharmaceutical sciences. From 1998 to 2007, Jonathan was with Pfizer where he was the clinical director for Lipitor, responsible for phase IIIB and IV trials as well as medical affairs functions. From 2002 to 2007, he held leadership roles in strategic groups with accountability for Pfizer’s intellectual property portfolio and pharmaceutical sciences process oversight. In 2009, Jonathan joined Amarin as the head of intellectual property and portfolio strategy and was a key member of the team that raised $70 million in 2009 to fund Amarin’s phase III cardiovascular program, leading to the approval of Vascepa.
Jonathan earned a Ph.D. and M.S. in biochemistry at the Albert Einstein College of Medicine in New York and an M.A. from Binghamton University.